LGX818 for Patients With BRAFV600 Mutated Tumors

Summary

The purpose of this signal seeking study is to determine whether treatment with LGX818 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study

Timeline

Start

2014-01-14

Primary completion

2015-09-01

Completion

2015-10-13

Outcome

Outcome not reported

Stopped (Enrollment): “Due to slow enrollment and lack of response observed during the enrollment period, the Sponsor decided to close study enrollment early on 28 January 2015”

Drugs

Indications